The guidelines include recommendations for first-, second-, and third-line therapy. The American Society of Clinical Oncology (ASCO) has updated its guidelines on the use of systemic therapy for ...
Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...
Fig 1. Summary: key ASCO guideline recommendations. AFP, alpha-fetoprotein; atezo + bev, atezolizumab + bevacizumab; durva + treme, durvalumab + tremelimumab; ECOG ...
Dr. John Gordan discusses the newest evidence-based guideline update from ASCO on systemic therapy for advanced hepatocellular carcinoma (HCC). He shares the updated recommendations for first-, second ...
Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...
Early detection of hepatocellular carcinoma (HCC) is crucial for improving patient outcomes and offers the best chance for curative treatment, making HCC screening a vital strategy for high-risk ...
Early-onset HCC incidence is declining, contrasting with rising colorectal cancer rates in young adults. Researchers defined early-onset HCC as occurring under 50 years, impacting future screening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results